Coronavirus drug maker SciClone Pharma eyes Hong Kong IPO

By Jonathan Breen
09 Sep 2020

SciClone Pharmaceutical (Holdings), a Chinese biopharmaceutical company that claims to have developed a drug to treat Covid-19, is seeking the greenlight to list in Hong Kong.

The firm, which counts global insurance giant Generali Group among its backers, develops and commercialises drugs, primarily for severe infection and oncology. SciClone’s main proprietary product, Zadaxin, has proven effective against Covid-19 and severe acute respiratory syndrome (Sars), another form of coronavirus, according to the prospectus.

China’s National ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial